---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-012335"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:45:28.902758+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# bioAffinity Technologies reports FY2023 revenue of $2.5M, up from $5K; CyPath Lung orders grow 350% in Q1 2024

## Summary
- FY2023 revenue $2.5M vs $5K in 2022; net loss $7.9M ($0.91/sh) vs $8.1M ($1.81/sh).
- Q4 2023 revenue $2.2M vs nil prior year; net loss $2.4M vs $1.7M.
- Cash and equivalents $2.8M at Dec 31, 2023.
- CMS final payment determination for CyPath Lung for 2024; CyPath Lung orders up 350% in Q1 2024 vs Q4 2023.
- Appointed Michael Dougherty as CFO; Dallas Coleman as National Director of Sales.

## SEC filing metadata
- accession: 0001493152-24-012335
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315224012335/0001493152-24-012335-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315224012335/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-012335
- JSON: https://secwatch.observer/filing/0001493152-24-012335.json
- Plain text: https://secwatch.observer/filing/0001493152-24-012335.txt

## Key facts
- Earnings Releases
  bioAffinity Technologies, Inc. reported the three and 12 months ended December 31, 2023 results: revenue $2.5 million, net income $7.9 million, EPS $0.91 per share.
  - Period: the three and 12 months ended December 31, 2023
  - Revenue: $2.5 million
  - Net income: $7.9 million
  - EPS: $0.91 per share
  - Result: reported results
  source text: expanding our market to fulfill the promise of early cancer detection and treatment.” Fourth Quarter Financial Results Revenue for the fourth quarter of 2023 was approximately $2.2 million, up from no revenue for the prior-year period. Revenue was derived from sales and services of the Company’s commercial laboratory, Precision Pathology Laboratory Services,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1712762/000149315224012335/0001493152-24-012335-index.htm
- Earnings Releases
  bioAffinity Technologies, Inc. reported the three and 12 months ended December 31, 2023 results: revenue $2.5 million, net income $7.9 million, EPS $0.91 per share.
  - Period: the three and 12 months ended December 31, 2023
  - Revenue: $2.5 million
  - Net income: $7.9 million
  - EPS: $0.91 per share
  - Result: reported results
  source text: today reported financial results for the three and 12 months ended December 31, 2023. Fiscal Year 2023 and Recent Highlights ● Reported fiscal year 2023 revenue of $2.5 million, a significant increase from $5,000 in 2022, driven by the September 2023 acquisition of Precision Pathology Laboratory Services (PPLS) and increasing sales of CyPath ® Lung,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1712762/000149315224012335/0001493152-24-012335-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.